Ongoing Clinical Trials for Metastases to Meninges
This article provides information about 2 ongoing clinical trials investigating treatments for metastases to meninges, a serious condition where cancer spreads to the protective membranes surrounding the brain and spinal cord. These studies are evaluating different immunotherapy and targeted therapy approaches to improve outcomes for patients with this challenging condition. (Also known as: Leptomeningeal disease, Leptomeningeal carcinomatosis).
Clinical trial locations
- Austria
- Germany
- Spain
Study of Nivolumab for Patients with Metastatic Solid Tumors and Leptomeningeal Disease
This trial is investigating nivolumab, an immunotherapy medication that helps the immune system fight cancer cells. What makes this study unique is that the medication is given directly into the fluid surrounding the brain and spinal cord through a special device called an Ommaya reservoir, rather than through a standard intravenous infusion.
Who can participate:
The study is looking for adults aged 18 and older who have leptomeningeal disease confirmed through spinal fluid testing or MRI scans. Participants must have a Karnofsky performance score greater than 50%, meaning they should be able to perform most daily activities with some assistance. They need to be able to receive treatment through an intraventricular catheter and must have adequate organ function. Women of childbearing potential and their male partners must agree to use effective birth control during treatment and for 150 days after the last dose.
Who cannot participate:
The study excludes patients outside the specified age range and those considered part of vulnerable populations who might need special protection or care. Interestingly, patients with leptomeningeal disease are listed in the exclusion criteria, though this appears to relate to specific characteristics not detailed in the trial information.
What the trial aims to discover:
The main goal is to determine the highest dose of nivolumab that can be safely administered directly into the spinal fluid and to evaluate its safety profile. Researchers will monitor participants for side effects and assess how long they live after receiving treatment. Regular check-ups, MRI scans, and neurological examinations will track the condition and treatment effects throughout the study, which is expected to conclude by September 30, 2026.
Treatment being tested:
Nivolumab is a PD-1 antibody that works by blocking a pathway cancer cells use to hide from the immune system. By blocking this pathway, the medication potentially allows the body’s natural defenses to better recognize and destroy cancer cells.
Study of Patritumab Deruxtecan for Patients with Brain Metastases from Advanced Breast or Lung Cancer and Leptomeningeal Disease from Solid Tumors
This trial is evaluating patritumab deruxtecan, a targeted therapy designed to deliver chemotherapy directly to cancer cells. The study focuses on three groups of patients: those with advanced breast cancer that has spread to the brain, those with non-small cell lung cancer with brain metastases, and those with leptomeningeal disease from any solid tumor.
Who can participate:
Adults aged 18 and older with confirmed diagnoses of specific cancer types can participate. For the breast cancer and lung cancer groups, patients must have newly diagnosed or progressing brain metastases measuring at least 10 mm on MRI scans. For the leptomeningeal disease group, patients must have newly diagnosed or progressing disease after radiotherapy and a life expectancy of at least 6 weeks. All participants must have adequate bone marrow, liver, and kidney function, and any side effects from previous treatments should be reduced to mild levels. Women of childbearing potential must use effective birth control during the study and for 7 months after treatment, while men must use birth control for 4 months after treatment.
Who cannot participate:
The study excludes patients with cancer types not specified in the protocol, those who have received certain interfering treatments, patients with severe medical conditions that could make participation unsafe, and those unable to follow study procedures. Pregnant or breastfeeding women cannot participate, nor can patients who have recently participated in another clinical trial or have a history of allergic reactions to the study medication.
What the trial aims to discover:
The study is organized into three groups, each focusing on different aspects of treatment effectiveness. The first two groups examine how well the treatment affects brain metastases in breast cancer and lung cancer patients, while the third group assesses overall survival rates at three months for patients with leptomeningeal disease. Regular monitoring includes imaging tests like MRI to track changes in condition. The trial is expected to conclude by September 30, 2025.
Treatment being tested:
Patritumab deruxtecan is an antibody-drug conjugate that targets cancer cells expressing the HER3 protein. It works by binding to the HER3 receptor on cancer cells and delivering chemotherapy directly to them, which helps destroy the cancer cells while potentially minimizing effects on healthy tissue. The medication is administered through an intravenous infusion.
Summary
These two clinical trials represent important research efforts to find effective treatments for metastases to the meninges, a challenging condition with limited treatment options. The studies take different approaches: one uses immunotherapy delivered directly into the spinal fluid, while the other uses a targeted antibody-drug conjugate delivered intravenously.
Geographically, the trials are distributed across Europe, with studies taking place in Germany, Austria, and Spain. The nivolumab trial focuses specifically on the intrathecal administration method, which is innovative for this type of immunotherapy, while the patritumab deruxtecan trial includes multiple patient groups, allowing researchers to evaluate the treatment’s effectiveness in both brain metastases and leptomeningeal disease from various cancer types.
Both trials have specific eligibility requirements regarding organ function, previous treatments, and contraception, reflecting the serious nature of these conditions and the need for careful patient selection. The studies are expected to provide valuable information about new treatment options for patients facing these difficult diagnoses over the next few years.